Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoLogix Applies for Provisional Patent Application For Innovative Treatment of Severe Sepsis

Abstract:
NanoLogix, Inc. (PINKSHEETS: NNLX) announced today that it has filed a provisional patent application with the U.S. Patent Office titled, "Antimicrobial Action of a Silver-Coated Nanotubular Dialysis Device."

NanoLogix Applies for Provisional Patent Application For Innovative Treatment of Severe Sepsis

SHARON, PA | Posted on February 20th, 2007

This provisional patent application is based around a new and unique methodology for treating severe sepsis and septic shock. The incidence of severe sepsis and septic shock is the major factor in over two hundred thousand deaths per year in the United States. During the past decades billions of dollars have been spent in developing treatment strategies for this major cause of morbidity and mortality. Almost all treatment strategies have been centered around the utilization of intravenous antibiotics. However, even today 20-35% of patients with severe sepsis and 40-60% of patients with septic shock die within thirty days, with further deaths occurring within the first six months of illness. Due to the fact that almost all of these patients must be treated in intensive care units, the cost of treating a single patient costs up to $10,000 per day, and the total cost to the American health care system is many billions of dollars per annum.

The NanoLogix invention treats bacteremia and septic shock by utilizing a silver nanoparticle-coated nanotubular dialysis unit for killing pathogenic micro-organisms present in a patient's blood stream. Prior to making this application NanoLogix scientists investigated this novel methodology against two bacterial strains (E.coli and Staphylococcus aureus) and one fungal strain (Candida albicans). In multiple experiments the pathogenic load of the micro-organisms went from colonies that were too numerous to count, down to zero or a very dramatically reduced number of colonies.

Mitchell S. Felder, M.D., the CEO and Chairman of the Board of NanoLogix, Inc. stated, "This is both a fascinating as well as truly innovative approach to conquering this major cause of hospital deaths worldwide. We hope to accelerate our investigation of this methodology, and are currently seeking to partner with a major university and/or health care organization. With further success and development, this technique could truly revolutionize the treatment of infectious diseases and save countless lives."

####

About NanoLogix
NanoLogix is an industry innovator in the research, development and commercialization of nano-biotechnologies, applications and processes. The Company owns or has the rights to 32 patented technologies. The Company is currently focused on the production of hydrogen from agricultural feedstock, industrial wastewater and municipal waste streams to create new sources of energy. NanoLogix is presently operating a hydrogen bioreactor at Welch's Food and has recently signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation. Additionally, NanoLogix develops and markets diagnostic test kits for use in early detection of infectious human diseases such as cancer, cystic fibrosis and AIDS, and owns a patent for the non-toxic induction of apoptosis ('cell suicide') for the treatment of cancer. For more information on the Company, visit http://www.nanologix.net.

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please click here

Contacts:
Investor Relations.
Andrew Barwicki
516.662.9461

Copyright © Market Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014

Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014

Unraveling the light of fireflies December 17th, 2014

First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014

Announcements

Atom-thick CCD could capture images: Rice University scientists develop two-dimensional, light-sensitive material December 20th, 2014

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

Aculon Hires New Business Development Director December 19th, 2014

Patents/IP/Tech Transfer/Licensing

Silicon Valley-Based Foresight Valuation Launches STR-IPô, a New Initiative for Startups to Discover the Value of Their Intellectual Property December 18th, 2014

Chemists Fabricate Novel Rewritable Paper: An attractive alternate to regular paper, UC Riverside-developed technology helps address increasing problems in environment and resource sustainability December 2nd, 2014

Dicerna Announces License Agreement with Tekmira to Advance Dicernaís PH1 Development Program November 17th, 2014

First genetic-based tool to detect circulating cancer cells in blood: NanoFlares light up individual cells if breast cancer biomarker is present November 17th, 2014

Energy

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

How does enzymatic pretreatment affect the nanostructure and reaction space of lignocellulosic biomass? December 18th, 2014

Iranian Scientists Use Nanotechnology to Increase Power, Energy of Supercapacitors December 18th, 2014

Lifeboat Foundation gives 2014 Guardian Award to Elon Musk December 16th, 2014

Nanobiotechnology

Scientists trace nanoparticles from plants to caterpillars: Rice University study examines how nanoparticles behave in food chain December 16th, 2014

FEI and Oregon Health & Science University Install a Complete Correlative Microscopy Workflow in Newly Built Collaborative Science Facility December 16th, 2014

UCLA engineers first to detect and measure individual DNA molecules using smartphone microscope December 15th, 2014

Biomimetic dew harvesters: Understanding how a desert beetle harvests water from dew could improve drinking water collection in dew condensers December 8th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE